Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme
- PMID: 18561312
- DOI: 10.1002/ijc.23648
Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme
Abstract
Glioblastoma Multiforme (GBM) is almost inevitably a fatal tumor of the brain with most individuals dying within 1 year of diagnosis. It is the most frequent brain tumor in adults. Dose-response studies showed that Cucurbitacin B inhibited 50% growth (ED(50)) of 5 human GBM cell lines in liquid culture at approximately 10(-7) M. Soft-gel assays demonstrated that nearly all of the GBM clonogenic cells were inhibited at 10(-8) M of Cucurbitacin B. FACS analysis found that the compound (10(-7) M, 24 hr) caused G2/M arrest. The GBM cells underwent profound morphologic changes within 15-30 min after exposure to Cucurbitacin B (10(-7) M), rounding up and losing their pseudopodia associated with disruption of actin and microtubules, as observed by immunoflourescence. Cucurbitacin B (10(-7) M) caused prominent multinucleation of the cells after they were pulse-exposed (48 hr) to the drug, washed and cultured in normal medium for an additional 2 days. The drug (10(-7) M, 3-24 hr) increased levels of p-p38, p-JNK and p-JUN in U87 and T98G GBM cell lines as seen by Western blot. Interestingly, alterations in cell morphology caused by Cucurbitacin B (10(-7) M) were blocked by the JNK inhibitor SP600125. In summary, Cucurbitacin B has a prominent anti-proliferative activity on GBM cells; and at least in part, the mode of action is by affecting the cytoskeleton, as well as, the JNK pathway. Clinical trails of this drug should be pursued in GBM.
Copyright 2008 Wiley-Liss, Inc.
Similar articles
-
Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.BMC Complement Altern Med. 2012 Oct 12;12:185. doi: 10.1186/1472-6882-12-185. BMC Complement Altern Med. 2012. PMID: 23062075 Free PMC article.
-
Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines.Int J Oncol. 2010 Sep;37(3):737-43. doi: 10.3892/ijo_00000723. Int J Oncol. 2010. PMID: 20664943 Free PMC article.
-
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).Oncogene. 2005 Jan 13;24(3):344-54. doi: 10.1038/sj.onc.1208225. Oncogene. 2005. PMID: 15531918
-
Modulation of Calcium Signaling in Glioblastoma Multiforme: A Therapeutic Promise for Natural Products.Mini Rev Med Chem. 2020;20(18):1879-1899. doi: 10.2174/1389557520666200807133659. Mini Rev Med Chem. 2020. PMID: 32767939 Review.
-
An Insight into Emerging Phytocompounds for Glioblastoma Multiforme Therapy.Cardiovasc Hematol Agents Med Chem. 2024;22(3):336-347. doi: 10.2174/0118715257262003231031171910. Cardiovasc Hematol Agents Med Chem. 2024. PMID: 37957904 Review.
Cited by
-
Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling.J Cancer Res Clin Oncol. 2010 Apr;136(4):603-10. doi: 10.1007/s00432-009-0698-x. Epub 2009 Oct 9. J Cancer Res Clin Oncol. 2010. PMID: 19816711
-
Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics.PLoS One. 2010 Nov 24;5(11):e14039. doi: 10.1371/journal.pone.0014039. PLoS One. 2010. PMID: 21124831 Free PMC article.
-
Modulation of Cytoskeleton, Protein Trafficking, and Signaling Pathways by Metabolites from Cucurbitaceae, Ericaceae, and Rosaceae Plant Families.Pharmaceuticals (Basel). 2022 Nov 10;15(11):1380. doi: 10.3390/ph15111380. Pharmaceuticals (Basel). 2022. PMID: 36355554 Free PMC article. Review.
-
Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.BMC Complement Altern Med. 2012 Oct 12;12:185. doi: 10.1186/1472-6882-12-185. BMC Complement Altern Med. 2012. PMID: 23062075 Free PMC article.
-
Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.Br J Pharmacol. 2010 Jun;160(4):998-1007. doi: 10.1111/j.1476-5381.2010.00741.x. Br J Pharmacol. 2010. PMID: 20590594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
